CPVC capacity utilization (Palar)
60-65%
N/A
12,000 ton CPVC plant at Palar running at 60-65% utilization as of Q3.
PLATINUM
Other
10 Feb 2026
Platinum Industries Ltd — Q3 FY26
Platinum Industries reported Q3 FY26 standalone revenue of ₹102.62 crore, up 31% YoY, driven by strong CPVC demand and capacity expansion.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Platinum Industries reported Q3 FY26 standalone revenue of ₹102.62 crore, up 31% YoY, driven by strong CPVC demand and capacity expansion. PAT grew 18% YoY to ₹12.93 crore, though EBITDA margin contracted to 15.8% due to higher CPVC mix and new plant costs. Management guided for >40% revenue growth in FY27 and a 35% CAGR through FY29, supported by the Palar facility ramp-up (CPVC at 60-65% utilization) and Egypt plant commissioning by September 2026. The company also entered pharma via a new subsidiary. Risks include margin pressure from product mix shift and execution delays in Egypt.
Key Numbers
Egypt plant capacity
60,000 tons
N/A
Egypt facility will have 60,000 tons total capacity; commercial production expected by September 2026.
India total capacity
60,000 tons
+100% vs earlier
India capacity doubled from 30,000 to 60,000 metric tons over last 2-3 years.
Egypt revenue target (3 years)
₹250-300 crore
N/A
Management targets 50% utilization of Egypt's 600 crore potential within 3 years.
Management Guidance
FY27 revenue growth >40%
Management expects standalone revenue growth exceeding 40% in FY27, driven by Palar ramp-up and Egypt commissioning.
Management guidance revenue35% CAGR from FY26 to FY29
Company targets a 35% compound annual growth rate over the next three years, excluding pharma business.
Management guidance growthEgypt commercial production by September 2026
Egypt plant construction to complete by end of May 2026, pre-commissioning in June, commercial production by September 2026.
Management guidance expansionPharma revenue in FY27
New pharma subsidiary (Rivardu Life Sciences) expected to generate revenue in FY27, though no specific figures provided.
Management guidance revenueKey Risks
Margin pressure from CPVC mix shift
Higher CPVC sales, which carry lower margins, have compressed overall EBITDA margins from 23% in FY24 to ~15% currently.
medium · data_observationEgypt plant execution delay
Egypt plant already delayed by 9-12 months; further delays could push revenue contribution beyond FY27.
high · management_commentaryPromoter stake sale
Promoter sold ~0.87% stake in Q3 for personal loans, raising concerns about future dilution.
low · analyst_questionLead-based product regulatory risk
Global shift away from lead stabilizers could impact Egypt's lead-focused capacity, though management claims machines can be converted.
medium · analyst_questionNotable Quotes
We expect to accelerate our growth trajectory targeting more than 40% revenue growth in financial year 2027 and a 35% CAGR from financial year 2026 to financial year 2029.
The product the new product has its own life cycle in terms of getting to its mature state... we were very successful in two quarters back to find the alternatives to make the formulation more effective.
If you talk about the strategic location is closer to the western world... 20 FTA agreements means almost 130 countries can import from us duty-free.
Frequently Asked Questions
What was Platinum Industries's revenue in Q3 FY26?
Platinum Industries reported revenue of ₹105 Cr in Q3 FY26, representing a +31% change compared to the same quarter last year.
What guidance did Platinum Industries management give for FY27?
FY27 revenue growth >40%: Management expects standalone revenue growth exceeding 40% in FY27, driven by Palar ramp-up and Egypt commissioning. 35% CAGR from FY26 to FY29: Company targets a 35% compound annual growth rate over the next three years, excluding pharma business. Egypt commercial production by September 2026: Egypt plant construction to complete by end of May 2026, pre-commissioning in June, commercial production by September 2026. Pharma revenue in FY27: New pharma subsidiary (Rivardu Life Sciences) expected to generate revenue in FY27, though no specific figures provided.
What are the key risks for Platinum Industries in FY27?
Key risks include Margin pressure from CPVC mix shift — Higher CPVC sales, which carry lower margins, have compressed overall EBITDA margins from 23% in FY24 to ~15% currently.; Egypt plant execution delay — Egypt plant already delayed by 9-12 months; further delays could push revenue contribution beyond FY27.; Promoter stake sale — Promoter sold ~0.87% stake in Q3 for personal loans, raising concerns about future dilution.; Lead-based product regulatory risk — Global shift away from lead stabilizers could impact Egypt's lead-focused capacity, though management claims machines can be converted..
Did Platinum Industries meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Platinum Industries Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.